Price6.42%   +0.76
(After Hours: 13.17 +0.58 +4.61%)
Jun-06-22 04:30AM Editas Medicine Reports Inducement Grants to New Chief Executive OfficerGlobeNewswire Inc.
Jun-03-22 11:31AM Editas (EDIT) Down 20.7% Since Last Earnings Report: Can It Rebound?Zacks Investment Research
May-18-22 06:45AM Editas Medicine Presents Data on SLEEK Gene Editing Technology at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire Inc.
May-13-22 11:52AM Why Editas Medicine's Shares Fell 28.9% This WeekThe Motley Fool
10:32AM These 5-Stock Samplers Have Gotten Whacked. And That's OKThe Motley Fool
May-13-22 10:30AM Editas' (EDIT) EDIT-301 Gets Orphan Drug Tag for Beta ThalassemiaZacks Investment Research
May-12-22 04:30AM Editas Medicine Receives FDA Orphan Drug Designation for EDIT-301 for the Treatment of Beta ThalassemiaGlobeNewswire Inc.
May-09-22 12:02PM Expert Ratings for Editas MedicineBenzinga
May-04-22 01:30AM Editas Medicine Presents Preclinical Data on EDIT-103 for Rhodopsin-associated Autosomal Dominant Retinitis Pigmentosa at the Association for Research in Vison and Ophthalmology ConferenceGlobeNewswire Inc.
11:54AM Editas' (EDIT) Q1 Loss Narrows, Revenues Beat EstimatesZacks Investment Research
May-04-22 07:55AM Editas Medicine (EDIT) Reports Q1 Loss, Tops Revenue EstimatesZacks Investment Research
06:45AM Editas Medicine Announces First Quarter 2022 Results and Business UpdatesGlobeNewswire Inc.
Apr-27-22 03:03AM Editas Medicine (EDIT) Expected to Beat Earnings Estimates: Can the Stock Move Higher?Zacks Investment Research
06:55AM Editas Medicine to Host Conference Call Discussing First Quarter 2022 Results and Corporate UpdateGlobeNewswire Inc.
Apr-19-22 06:20AM 3 Ominous Reasons to Avoid This Biotech PioneerThe Motley Fool
Apr-14-22 07:30AM Editas Medicine Appoints Gilmore O’Neill as Chief Executive OfficerGlobeNewswire Inc.
Apr-13-22 10:45AM CRISPR Stocks Are Huge -- Here's Why They'll Get Even Bigger by 2030The Motley Fool
Apr-12-22 11:47AM Editas (EDIT) Begins Dosing Pediatric Patients in Gene Drug StudyZacks Investment Research
Mar-21-22 07:44AM Editas (EDIT) Soars 6.3%: Is Further Upside Left in the Stock?Zacks Investment Research
Mar-16-22 12:27PM Who Benefits From Amazon's Stock Split?The Motley Fool
Mar-01-22 07:51AM The Daily Biotech Pulse: Legend Biotech, CTI Biopharma Receive FDA Approvals, AbbVie Announces Delay In Skyrizi Review, Editas Gains On CRISPR Patent ResolutionBenzinga
Feb-28-22 04:01AM Editas Medicine Announces Favorable Decision from U.S. Patent and Trademark Office in CRISPR Patent InterferenceGlobeNewswire Inc.
Feb-25-22 11:51AM Editas' (EDIT) Q4 Loss Narrows, Revenues Trump EstimatesZacks Investment Research
11:08AM Expert Ratings For Editas MedicineBenzinga
Feb-24-22 08:01AM The Daily Biotech Pulse: Orphazyme Plunges On Regulatory Setback In Europe, Pulmonx Earnings Disappoint, Amicus Declines To Spin Off Genetic Medicine CompanyBenzinga
07:45AM Editas Medicine (EDIT) Reports Q4 Loss, Tops Revenue EstimatesZacks Investment Research
Feb-24-22 06:30AM Editas Medicine Announces Fourth Quarter and Full Year 2021 Results and Business UpdatesGlobeNewswire Inc.
Feb-23-22 11:44AM Drug/Biotech Stocks' Q4 Earnings on Feb 24: MRNA, EBS & MoreZacks Investment Research
Feb-20-22 08:06AM The Week Ahead In Biotech (Feb. 20-26): Reata Awaits FDA Decision, Bausch Health, Moderna Lead Earnings News FlowBenzinga
Feb-17-22 03:03AM Will Editas Medicine (EDIT) Report Negative Earnings Next Week? What You Should KnowZacks Investment Research
Feb-16-22 06:15AM Editas Medicine to Host Conference Call Discussing Fourth Quarter and Full Year 2021 Results and Corporate UpdateGlobeNewswire Inc.
Feb-14-22 12:21PM Orphazyme (ORPH) Up on Plans of NDA Resubmission for Rare DrugZacks Investment Research
Feb-11-22 12:02PM Ultragenyx's (RARE) Q4 Earnings & Revenues Miss EstimatesZacks Investment Research
Feb-08-22 12:40PM Editas Suddenly Terminates Chief Medical Officer Without An ExplanationBenzinga
08:29AM The Daily Biotech Pulse: Pfizer, Amgen Shares Slip On Earnings, Editas Terminates Chief Medical Officer, Biogen Licenses Preclinical Rheumatoid Arthritis BiosimilarBenzinga
Feb-07-22 01:05AM Immunovant (IMVT) Reports Wider-Than-Expected Loss in Q3Zacks Investment Research
Feb-02-22 06:40AM 2 Biotech Stocks That Could Skyrocket This YearThe Motley Fool
Jan-29-22 10:30AM 3 Growth ETFs to Consider Buying During This CorrectionThe Motley Fool
Jan-19-22 10:46AM Editas (EDIT) Focuses on Developing Gene-Editing Eye DrugZacks Investment Research
Jan-13-22 05:24AM Why Editas Medicine Stock Is Tumbling This WeekThe Motley Fool
Editas Medicine, Inc. operates as a genome editing company. It focuses on treating patients with genetically defined diseases by correcting their disease causing genes. The company develops a proprietary genome editing platform based on CRISPR technology to target genetically defined diseases with an initial focus on debilitating illnesses where there are no approved treatments. It develops EDIT-101 for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. The company also develops other therapies for eye diseases, such as Herpes Simplex Virus 1 that causes lifelong infections primarily leading to ocular and oral disease; and Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss. In addition, it develops hematopoietic stem cells for treating sickle cell disease and beta thalassemia. Editas Medicine, Inc. has a collaboration and license agreement with Juno Therapeutics, Inc. for the research and development of engineered T cells with chimeric antigen receptors and T cell receptors; and strategic alliance and option agreement with Allergan Pharmaceuticals International Limited for the research and development of medicines for ocular diseases. The company was formerly known as Gengine, Inc. and changed its name to Editas Medicine Inc. in November 2013. Editas Medicine, Inc. was founded in 2013 and is based in Cambridge, Massachusetts.
Cap:    |  Volume (24h):